Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market & Industry Briefs

Executive Summary

Brief summaries of recent medtech market and industry developments. This month we cover secondary buyers as an exit strategy for Boston Scientific and others; a review of medtech dealmaking in the first quarter of 2008, and US markets for patient monitoring products.

You may also be interested in...



TriVascular2: A New Beginning

Boston Scientific agreed to divest itself of its TriVascular abdominal aortic aneurysm company, selling it for $65 million to MPM Capital, New Enterprise Associates, Kearny Venture Partners and Delphi Ventures.

Hemodynamic Monitoring Enters a New Era

As critical care migrates from intensive care units to other areas of the hospital, hemodynamic monitors--essential for patient diagnosis and prognosis--must make the move as well. At this year's annual meeting of the Society of Critical Care Medicine, clinicians and researchers discussed the need and the market challenges for hemodynamic monitoring technologies that are simpler to use, less invasive and allow for earlier diagnosis of sepsis and shock.

M&A In Medical Devices: A More Robust Climate? Yes & No

Over the last three years, deal values in medical device M&A have hit all time highs, with more big deals done than ever before. Still, even with deal values soaring, device M&A remains a small-stakes game. IN VIVO looks at dealmaking in medtech by therapeutic and industry segments.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel